Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

A Novel Bicyclic Peptide Inhibitor of Plasma Kallikrein, THR 149, for the Treatment of Diabetic Macular Edema (DME): Clinical and Pre Clinical Evidence

Francesco Bandello, RaminTadayoni, Sunil Patel, Pravin Dugel, Brian Berger, Mitchell Fineman, Glenn Jaffe, Jeffrey Heier, Tine Van Bergen, Isabelle Etienne, Petra Kozma, Arshad M. Khanani

Publication date:

September, 2021

Attachment:

Bandello et al THR-149_ EURETINA_2021 _FINAL.pdf

Search form

Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

A Novel Bicyclic Peptide Inhibitor of Plasma Kallikrein, THR 149, for the Treatment of Diabetic Macular Edema (DME): Clinical and Pre Clinical Evidence